Editorial: infliximab or adalimumab as first‐ or second‐line anti‐TNF—conflicting evidence

LINKED CONTENT This article is linked to Visuri et al papers. To view these articles, visit https://doi.org/10.1111/apt.16525 and https://doi.org/10.1111/apt.16569

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2021-09, Vol.54 (6), p.846-847
Main Authors: Haydek, John P., Scott, Frank I.
Format: Article
Language:English
Subjects:
Infliximab
Monoclonal antibodies
Tumor necrosis factor-α
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:LINKED CONTENT This article is linked to Visuri et al papers. To view these articles, visit https://doi.org/10.1111/apt.16525 and https://doi.org/10.1111/apt.16569
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.16555